Walden Group Healthcare M&A Blog

  • J&J to buy Abbott Medical Optics for $4.3b.

    10/25/2016
    Johnson & Johnson (NYSE: JNJ), a $74.3b manufacturer of pharmaceuticals, medical devices and consumer healthcare products, has agreed to buy Abbott Medical Optics Inc, a global ophthalmic surgical and eye care products company and a unit of Abbott Labs. The deal greatly expands J&J's $7b eye care segment, by adding ophthalmic products...
    Read More
  • Abbott is buying St.Jude Medical Further Consolidating the Medical Device Sector

    05/05/2016
    Abbott Laboratories (NYSE:ABT), a $20.4b maker of diagnostics, medical devices, pharmaceuticals and nutritionals, has agreed to buy St. Jude Medical Inc. (NASDAQ:STJ), a major maker of devices for cardiac rhythm management, cardiovascular, and atrial fibrillation. St. Jude Medical's strong positions in heart failure devices, atrial fibrillation...
    Read More
  • What to Expect for 2016 Healthcare M&A Activity

    01/24/2016
    Recent volatility in worldwide markets, weakness in China, terrorism, softness in Europe and emerging markets, budget issues, and healthcare reform dislocations are among the dynamics that have clouded the 2016 picture for healthcare M&A. Here, we help clarfty things. China China is moving from a manufacturing and investment orientation to a...
    Read More
  • Walden Advises Halma plc (LSE:HLMA) in its acquisition of Visiometrics, S.L. (Barcelona, Spain)

    12/19/2015
    The Walden Group is pleased to announce that it has advised Halma plc, a UK-based public company, in its acquisition of Visiometrics, S.L., located outside Barcelona, Spain. On Halma's behalf, The Walden Group identified Visiometrics as a strategic fit, cultivated a relationship with Visiometrics' principals, advised Halma on the transaction, and...
    Read More
  • Medtronic's 2015 Deal Appetite Whetted By Tax Savings

    10/27/2015
    Medtronic's most recent acquistion target was Lazarus Effect, a maker of stroke diagnostic devices. After obtaining European approval, Lazarus Effect is working to get U.S. approval for the ReCover brain blot clot removal device, which works with Medtronic 's Solitaire stent that can be deployed in the brain to scoop out vessel-blocking clots that...
    Read More